These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 19179909)
21. Bevacizumab in lung cancer: lackluster performance and unjustified expense? Dasanu CA J Oncol Pharm Pract; 2012 Sep; 18(3):381-2. PubMed ID: 22777997 [TBL] [Abstract][Full Text] [Related]
22. Intramedullary spinal cord hemorrhage after treatment with bevacizumab in a long-term survivor with metastatic non-small-cell lung cancer. Arreola KN; Ying J; Hughes R; Gerber DE; Kim DW J Thorac Oncol; 2014 Aug; 9(8):e60-1. PubMed ID: 25157780 [No Abstract] [Full Text] [Related]
23. How should we use bevacizumab in patients with non-small cell lung cancer? Kim YH; Mishima M J Thorac Oncol; 2011 Dec; 6(12):2145-6. PubMed ID: 22088996 [No Abstract] [Full Text] [Related]
24. Bevacizumab in non-small cell lung cancer: an overview of practice in the era of molecular testing. Snee M Clin Oncol (R Coll Radiol); 2014 Aug; 26(8):468-72. PubMed ID: 24909702 [TBL] [Abstract][Full Text] [Related]
25. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. Crinò L; Dansin E; Garrido P; Griesinger F; Laskin J; Pavlakis N; Stroiakovski D; Thatcher N; Tsai CM; Wu YL; Zhou C Lancet Oncol; 2010 Aug; 11(8):733-40. PubMed ID: 20650686 [TBL] [Abstract][Full Text] [Related]
26. Osteonecrosis of the humeral head in a patient with non-small cell lung cancer receiving bevacizumab. Koczywas M; Cristea MC J Thorac Oncol; 2011 Nov; 6(11):1960-1. PubMed ID: 22005475 [No Abstract] [Full Text] [Related]
27. The proportion of patients with metastatic non-small cell lung cancer potentially eligible for treatment with bevacizumab: a single institutional survey. Velcheti V; Viswanathan A; Govindan R J Thorac Oncol; 2006 Jun; 1(5):501. PubMed ID: 17409907 [No Abstract] [Full Text] [Related]
28. Bevacizumab for the treatment of advanced non-small-cell lung cancer. Manegold C Expert Rev Anticancer Ther; 2008 May; 8(5):689-99. PubMed ID: 18471042 [TBL] [Abstract][Full Text] [Related]
29. [Antiangiogenic agents: current limits in thoracic oncology]. Dansin E; Lauridant G; Chahine B Bull Cancer; 2012 Nov; 99(11):1083-91. PubMed ID: 23113985 [TBL] [Abstract][Full Text] [Related]
30. Splenic infarction and bevacizumab. Malka D; Van den Eynde M; Boige V; Dromain C; Ducreux M Lancet Oncol; 2006 Dec; 7(12):1038. PubMed ID: 17138227 [No Abstract] [Full Text] [Related]
31. Biological agents in non-small cell lung cancer: a review of recent advances and clinical results with a focus on epidermal growth factor receptor and vascular endothelial growth factor. Kelly K; Huang C J Thorac Oncol; 2008 Jun; 3(6):664-73. PubMed ID: 18520811 [TBL] [Abstract][Full Text] [Related]
34. Bevacizumab in non small cell lung cancer. Sandler A Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4613-6. PubMed ID: 17671151 [TBL] [Abstract][Full Text] [Related]
35. Treatment of pulmonary epithelioid hemangioendothelioma with bevacizumab. Kim YH; Mishima M; Miyagawa-Hayashino A J Thorac Oncol; 2010 Jul; 5(7):1107-8. PubMed ID: 20581581 [No Abstract] [Full Text] [Related]
36. Erlotinib plus bevacizumab is effective in EGFR-mutant NSCLC. Cancer Discov; 2014 Nov; 4(11):OF18. PubMed ID: 25367959 [TBL] [Abstract][Full Text] [Related]
38. The use of bevacizumab in non-small cell lung cancer: an update. Lauro S; Onesti CE; Righini R; Marchetti P Anticancer Res; 2014 Apr; 34(4):1537-45. PubMed ID: 24692680 [TBL] [Abstract][Full Text] [Related]
39. Antiangiogenic agents for the treatment of nonsmall cell lung cancer: characterizing the molecular basis for serious adverse events. Wu S; Keresztes RS Cancer Invest; 2011 Aug; 29(7):460-71. PubMed ID: 21740083 [TBL] [Abstract][Full Text] [Related]